



Irina Skylar-Scott

Clinical Associate Professor, Adult Neurology

CLINICAL OFFICE (PRIMARY)

213 Quarry Rd

Palo Alto, CA 94303

Tel (650) 736-4310 Fax (650) 498-6045

Bio

BIO

Dr. Skylar-Scott is a board-certified, fellowship-trained cognitive and behavioral neurologist and clinical assistant professor at Stanford University. She is a Diplomate of the American Board of Psychiatry and Neurology as well as the United Council for Neurologic Subspecialties in Behavioral Neurology and Neuropsychiatry.

Her clinical interests include the treatment of cognitive and behavioral impairment due to Alzheimer's disease, Parkinson's disease, Lewy body dementia, posterior cortical atrophy, primary progressive aphasia, frontotemporal dementia, vascular dementia, primary age-related tauopathy, and limbic-predominant age-associated TDP-43 encephalopathy, among other disorders of cognition and behavior.

Her research interests include clinical trials for Alzheimer's disease and how social and intellectual engagement can affect cognition. She has also investigated impaired consciousness in epilepsy and biomarkers for assessing Duchenne muscular dystrophy. Prior to joining Stanford, Dr. Skylar-Scott was a fellow in the Center for Alzheimer's Research and Treatment (CART) in the Department of Neurology at Harvard Medical School/Brigham and Women's Hospital. She also completed her undergraduate degree at MIT, her MD at Yale, and her residency at Harvard.

Dr. Skylar-Scott's work has appeared in *Neurology*, *Alzheimer's Research and Therapy*, *Pediatric Neurology*, the *Journal of Ultrasound in Medicine*, *Muscle & Nerve*, and *Epilepsia*. She also has also been invited to write book chapters on Alzheimer's disease, normal pressure hydrocephalus, Parkinson's disease dementia and Lewy body dementia, and the cognitive and psychiatric consequences of neuroimmunological disorders published by Elsevier and McGraw-Hill.

Presentations by Dr. Skylar-Scott have focused on prevention of cognitive decline in at-risk elderly people, cognitive and neuropsychiatric manifestations of Parkinson's disease, human prion diseases, and other topics. She has presented at meetings held by the American Academy of Neurology (AAN), the American Neurological Association (ANA), and the American Academy of Neuromuscular and Electrophysiology (AANEM).

For her research and scholarship, Dr. Skylar-Scott has earned honors from the American Academy of Neurology (AAN) and the Howard Hughes Medical Institute (HHMI). She was honored to receive the Golseth Young Investigator Award from the American Association of Neuromuscular &

Electrodiagnostic Medicine. In addition, she won the Action Duchenne International Conference First Prize Poster for her research in Duchenne muscular dystrophy.

Dr. Skylar-Scott is a member of the American Neurological Association and American Academy of Neurology. Every year, she walks to raise money for Alzheimer's disease and Lewy body dementia.

CLINICAL FOCUS

- Neurology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Adult Neurology

PROFESSIONAL EDUCATION

- Board Certification: Behavioral Neurology and Neuropsychiatry, United Council for Neurologic Subspecialties (2022)
- Board Certification, United Council for Neurologic Subspecialties , Behavioral Neurology and Neuropsychiatry (2022)
- Medical Education: Yale School Of Medicine (2014) CT
- Fellowship: Brigham and Women's Hospital Neurology Fellowship (2020) MA
- Board Certification: Neurology, American Board of Psychiatry and Neurology (2018)
- Residency: Beth Israel Deaconess Medical Center Neurology Residency (2018) MA
- Internship: Yale New Haven Medical Center Transitional Year (2015) CT

Research & Scholarship

CLINICAL TRIALS

- ALS PET-MRI, Recruiting

Publications

PUBLICATIONS

- **Public Health.** *Alzheimer's & dementia : the journal of the Alzheimer's Association*
Lu, O., Trelle, A. N., Young, C. B., Mormino, E. C., Wagner, A. D., He, Z., Carr, V. A., Sha, S. J., Vossler, H., Romero, A., Park, J., Skylar-Scott, I. A.
2025; 21 Suppl 6 (Suppl 6): e107011
- **Drug Development.** *Alzheimer's & dementia : the journal of the Alzheimer's Association*
Kmiecik, M., Chu, M., Zhou, A., Skylar-Scott, I. A., Samudra, N., Tripathi, P., Coburn, M., Wilson, T. N., He, Z., Haddad, F., Wyss-Coray, T., Sha, S. J., Greicius, et al
2025; 21 Suppl 5: e106859
- **Plasma A β 42/A β 40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum.** *Alzheimer's & dementia : the journal of the Alzheimer's Association*
Trelle, A. N., Young, C. B., Vossler, H., Ramos Benitez, J., Cody, K. A., Mendiola, J. H., Swarovski, M. S., Guen, Y. L., Feinstein, I., Butler, R. R., Channappa, D., Romero, A., Park, et al
2024
- **Public Health.** *Alzheimer's & dementia : the journal of the Alzheimer's Association*
Lu, O., Mormino, E., He, Z., Carr, V. A., Trelle, A. N., Young, C. B., Romero, A., Vossler, H., Park, J., Skylar-Scott, I. A.
2024; 20 Suppl 7: e084160
- **Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies.** *Frontiers in neurology*
Lu, O., Kouser, T., Skylar-Scott, I. A.
2023; 14: 1241339

- **Lewy Body Dementia: An Overview of Promising Therapeutics.** *Current neurology and neuroscience reports*
Skylar-Scott, I. A., Sha, S. J.
2023
- **Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.** *Alzheimer's research & therapy*
Wilson, E. N., Young, C. B., Ramos Benitez, J., Swarovski, M. S., Feinstein, I., Vandijck, M., Le Guen, Y., Kasireddy, N. M., Shahid, M., Corso, N. K., Wang, Q., Kennedy, G., Trelle, et al
2022; 14 (1): 172